Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) Gross Profit: 2016-2024

Historic Gross Profit for UroGen Pharma (URGN) over the last 9 years, with Dec 2024 value amounting to $81.5 million.

  • UroGen Pharma's Gross Profit rose 6.39% to $24.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $84.9 million, marking a year-over-year increase of 5.23%. This contributed to the annual value of $81.5 million for FY2024, which is 11.13% up from last year.
  • Per UroGen Pharma's latest filing, its Gross Profit stood at $81.5 million for FY2024, which was up 11.13% from $73.4 million recorded in FY2023.
  • UroGen Pharma's 5-year Gross Profit high stood at $81.5 million for FY2024, and its period low was $10.8 million during FY2020.
  • For the 3-year period, UroGen Pharma's Gross Profit averaged around $70.5 million, with its median value being $73.4 million (2023).
  • Data for UroGen Pharma's Gross Profit shows a peak YoY soared of 59,844.44% (in 2020) over the last 5 years.
  • Over the past 5 years, UroGen Pharma's Gross Profit (Yearly) stood at $10.8 million in 2020, then skyrocketed by 297.45% to $42.9 million in 2021, then spiked by 32.22% to $56.7 million in 2022, then climbed by 29.36% to $73.4 million in 2023, then increased by 11.13% to $81.5 million in 2024.